SAN JOSE, Calif., Feb. 15, 2018 /PRNewswire/ -- Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that providestechnology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report fourth quarter and full year 2017 financial results before the open of U.S. financial markets on
The conference call may be accessed by dialing 877-359-9508 for domestic callers and 224-357-2393 for international callers. Please specify to the operator that you would like to join the "Semler Fourth Quarter and Full Year 2017 Financial Results Call, conference ID#: 6778765." The conference call will be archived on Semler's website at www.semlerscientific.com.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is an emerging growth company that provides technology and software solutions to improve the clinical effectiveness and efficiency of healthcare providers. Its mission is to develop, manufacture and market innovative proprietary products and services that assist its customers in evaluating and treating chronic diseases. Semler Scientific's first patented and U.S. Food and Drug Administration, or FDA, cleared product, introduced commercially in 2011, measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015, Semler Scientific received FDA 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015 to more comprehensively evaluate its customers' patients for risk of heart attacks and strokes. Semler Scientific believes it is positioned to provide valuable information to its insurance company and physician customers, which in turn permits them to better guide patient care. Additional information about Semler Scientific can be found at www.semlerscientific.com.
CONTACT:Susan A. NoonanS.A. Noonan Communicationssusan@sanoonan.com212 966 3650
View original content:http://www.prnewswire.com/news-releases/semler-to-report-fourth-quarter-and-full-year-2017-financial-results-and-host-conference-call-on-february-28-2018-300598880.html
SOURCE Semler Scientific, Inc.
Subscribe to our Free Newsletters!
Kleine Levin (KLS) or sleeping beauty syndrome is a rare neurological disorder that primarly ...
LADA or Latent Autoimmune Diabetes of Adulthood is a form of type 1 autoimmune diabetes that can be ...
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...View All